Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.110.90 CHF
Change Today -3.10 / -2.72%
Volume 55.1K
As of 11:43 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

basilea pharmaceutica-reg (BSLN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/9/15 - SFr.125.50
52 Week Low
10/16/14 - SFr.79.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

basilea pharmaceutica-reg (BSLN) Related Businessweek News

No Related Businessweek News Found

basilea pharmaceutica-reg (BSLN) Details

Basilea Pharmaceutica AG, together with its subsidiaries, operates as an integrated biopharmaceutical company in Switzerland, China, and internationally. The company focuses on the discovery, development, and commercialization of pharmaceutical products in the therapeutic areas of bacterial and fungal infections, and oncology. It offers Toctino, a therapy for the treatment of adult patients with severe chronic hand eczema, who do not respond to potent topical corticosteroids; and Ceftobiprole, a bactericidal antibiotic for the treatment of hospital and community-acquired pneumonia under the brand name of Zevtera. The company is also developing Isavuconazole, an antifungal drug for the treatment of invasive fungal infections, which is under regulatory review by the European Medicines Agency and the U.S. Food and Drug Administration; BAL30072, a monosulfactam antibiotic with bactericidal activity against multidrug-resistant gram-negative bacteria under Phase I clinical development; and BAL101553, a small-molecule anti-cancer drug in Phase IIa clinical development. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

230 Employees
Last Reported Date: 02/12/15
Founded in 2000

basilea pharmaceutica-reg (BSLN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.1.0M
Compensation as of Fiscal Year 2014.

basilea pharmaceutica-reg (BSLN) Key Developments

Basilea Pharmaceutica Ltd. Enters into License Agreement for Novel PanRAF Kinase Inhibitors with Consortium of Organizations

Basilea Pharmaceutica Ltd. reported that it has entered into a license agreement for novel panRAF kinase inhibitors with a consortium of organizations including The Institute of Cancer Research, London, Cancer Research Technology, the Wellcome Trust and The University of Manchester. The agreement grants Basilea exclusive worldwide rights to develop, manufacture and commercialize novel panRAF kinase inhibitors which originate from research at The Institute of Cancer Research by scientists funded by Cancer Research UK and the Wellcome Trust. RAF kinases play an important role in tumor cell proliferation. The oral, small molecule panRAF inhibitors target BRAF and other growth pathways relied upon by resistant tumor cells. These properties allow anti-cancer activity in a range of tumor models including tumors resistant to anti-BRAF therapy associated with a number of marketed anti-cancer drugs. The lead compound is anticipated to start clinical phase 1 testing in 2015. Under the terms of the agreement, the consortium will lead clinical phase 1 development for the lead compound. Basilea will assume full operational responsibility thereafter. The consortium receives an upfront payment and is eligible to potential milestone payments on achievement of pre-specified clinical, regulatory and commercial milestones, as well as tiered royalties on future net sales.

Basilea Pharmaceutica AG - Special Call

To update on U.S. FDA approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis

Basilea Reports U.S. FDA Approval of Isavuconazole for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Basilea Pharmaceutica Ltd. announced that the U.S. Food and Drug Administration (FDA) approved Astellas' New Drug Application (NDA) for the use of isavuconazole for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). These are life-threatening fungal infections predominantly occurring in immunocompromised patients. Basilea's partner Astellas will market the drug as CRESEMBA(R) (isavuconazonium sulfate) in the United States. Isavuconazole is being co-developed with Astellas Pharma Inc. Basilea holds full global rights to isavuconazole outside the U.S. and Canada where Astellas is the exclusive license holder. A CHF 30 million milestone payment from Astellas is associated with the approval of isavuconazole for the treatment of invasive aspergillosis in the United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSLN:SW SFr.110.90 CHF -3.10

BSLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSLN.
View Industry Companies

Industry Analysis


Industry Average

Valuation BSLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.0x
Price/Book 21.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BASILEA PHARMACEUTICA-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at